BACKGROUND: There are a limited number of publications on the management of
gynecologic/obstetric events in female patients with hereditary angioedema caused by C1 …

Methods Retrospective review using a purpose-designed questionnaire of 61 C1INH-HAE
patients from 5 hospitals specialized in the management of HAE in Spain. The outcomes …

OBJECTIVE: The course of hereditary angioedema (HAE) and the efficacy and safety of
human C1-INH concentrate were appraised during pregnancy and the postpartum period, in …

Three types of hereditary angioedema (HAE) have been described: two are due to C1
inhibitor (C1-INH) deficiency (C1-INH-HAE types I and II) and one is characterized by normal …

OBJECTIVE: Fluctuations in sex hormones can trigger angioedema attacks in women with
hereditary angioedema. Combined oral contraceptive therapies, as well as pregnancy, can …

OBJECTIVE: The objective of the study was to investigate the rates and characteristics of
hereditary angioedema (HAE) attacks associated with pregnancy, delivery, and the …

To cite this article: Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M. Standard care
impact on angioedema because of hereditary C1 inhibitor deficiency: a 21‐month …

Background Acquired angioedema due to C1-inhibitor deficiency (C1-INH-AAE) is a rare
disease with no prevalence data or approved therapies. Objective To report data on patients …

Background The treatment of hereditary angioedema (HAE) has undergone dramatic
changes as newer medicines have become available in recent years. Optimal care of these …

C1 inhibitor deficiency (hereditary angioedema [HAE]) is a rare disorder for which there is a
lack of consensus concerning diagnosis, therapy, and management, particularly in Canada …